Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients

NCT00151840 is registered in ClinicalTrials.gov with Prothya Biosolutions as lead sponsor.

NCT NCT00151840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00151840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of IVIG-L (Human Normal Immunoglobulin for Intravenous Use)in Idiopathic Thrombocytopenic Purpura (ITP)Patients
Lead sponsor
Prothya Biosolutions
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2001
Completion date
March 31, 2002
Enrollment
20
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

purpura, thrombocytopenic, idiopathic